Medifast Inc (MED)
Medifast Inc brought in $299.6M of revenue over the twelve months to September 30, 2026, down 30.3% from a year earlier. It posted a net loss of $40.9M. Operating cash flow minus capital spending left $1.2M of free cash flow in fiscal 2025. At September 30, 2026 it held $58.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 26, 2026.
Key facts about Medifast Inc
- Net worth
- Medifast Inc has a market value (market cap) of $147.4M at the latest share price, and shareholders' equity of $180.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $385.8M (-36.0% year on year), with a net loss of $18.7M. Over the 12 months to September 30, 2026: revenue $299.6M, net loss $40.9M.
- Cash flow
- In fiscal 2025 operations brought in $6.9M of cash; after $5.6M of capital spending, free cash flow was $1.2M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 26, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Medifast Inc's next report is expected around February 16, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Medifast Inc does
Medifast Inc is registered with the SEC under industry code SIC 2090 (Miscellaneous Food Preparations & Kindred Products). Its shares trade on NYSE under the ticker MED.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $385.8M | -$18.7M | -$1.70 | $1.2M |
| 2024 | $602.5M | $2.1M | $0.19 | $17M |
| 2023 | $1.1B | $99.4M | $9.10 | $141.2M |
| 2022 | $1.6B | $143.6M | $12.73 | $177.9M |
| 2021 | $1.5B | $164M | $13.89 | $60.3M |
| 2020 | $934.8M | $102.9M | $8.68 | $139.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where MED ranks in Consumer staples
Dividends
It paid out $195K in cash dividends.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $0.00 | $195K | n/a |
| 2024 | $0.00 | $715K | 34% |
| 2023 | $4.95 | $73M | 73% |
| 2022 | $6.56 | $71.6M | 50% |
| 2021 | $5.68 | $63.9M | 39% |
| 2020 | $4.52 | $53.2M | 52% |
Latest SEC filings
What Medifast Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 26, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 19% to $72M versus the same quarter last year; diluted EPS -$1.57 versus -$0.21.
- October 26, 2026
- August 21, 2026Activist stake changed SCHEDULE 13D/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 3, 2026
- August 3, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 28% to $76.4M versus the same quarter last year; diluted EPS -$0.28 versus $0.22.
- August 3, 2026
- July 29, 2026Passive stake changed SCHEDULE 13G/A
What is MED worth? A DCF from its reported cash flow
Insider trades
What the people running Medifast Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $1.5M and sold $226.3K worth of shares in the last 90 days. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 4, 2026 | Kiai ParsaDirector | Boughtindirect | 661 | $8.6K |
| October 28, 2026 | Kiai ParsaDirector | Boughtindirect | 5,399 | $66.1K |
| October 28, 2026 | Kiai ParsaDirector | Boughtindirect | 158 | $1.9K |
| September 29, 2026 | Chard Daniel RDirector | Soldpre-planned (10b5-1), indirect | 9,544 | $112K |
| September 28, 2026 | Chard Daniel RDirector | Soldpre-planned (10b5-1), indirect | 9,545 | $114.3K |
| August 26, 2026 | Kiai ParsaDirector | Boughtindirect | 41,975 | $514.7K |
| August 26, 2026 | Kiai ParsaDirector | Boughtindirect | 1,175 | $14.4K |
| August 24, 2026 | Kiai ParsaDirector | Boughtindirect | 4,211 | $50.5K |
Who owns MED
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Steamboat Capital Partners, LLC13D, may seek influence with 1 related filers | 7.1% | August 21, 2026 |
| Renaissance Technologies LLC13G, passive with 1 related filers | 6.96% | May 14, 2026 |
| Susquehanna Portfolio Strategies, LLC13G, passive with 1 related filers | 5.3% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 113 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Renaissance Technologies LLC | 778,610 | +4,900 |
| Steamboat Capital Partners, LLC | 706,699 | -891 |
| Two Sigma Investments, LP | 481,381 | +143,223 |
| Vanguard Capital Management LLC | 446,614 | +2,147 |
| Charles Schwab Investment Management Inc | 396,996 | -234,543 |
| BlackRock, Inc. | 369,503 | -574,950 |
| Dimensional Fund Advisors LP | 363,394 | +1,632 |
| American Century Companies Inc | 318,911 | +94,631 |
| Morgan Stanley | 292,508 | -32,804 |
| Goldman Sachs Group Inc | 243,085 | +89,914 |
| Marshall Wace, Llp | 241,649 | new |
| Aqr Capital Management LLC | 236,434 | +90,859 |
| Peapod Lane Capital LLC | 222,576 | +3,513 |
| Lido Advisors, LLC | 220,337 | +37,302 |
| Trexquant Investment LP | 212,684 | +32,603 |
| Jane Street Group, LLC | 164,881 | +38,474 |
| Commons Capital, LLC | 149,916 | +111,916 |
| Quinn Opportunity Partners LLC | 127,112 | 0 |
| Geode Capital Management, LLC | 121,071 | -132,244 |
| Bridgeway Capital Management, LLC | 117,078 | -40,000 |
Insiders
8 insiders reported holding 580,689 shares in total, about $7.7M at the last price.
| Holder | Shares |
|---|---|
| Chard Daniel RChairman & CEO, Director | 318,842130,609 held indirectly |
| Maloney James P.Chief Financial Officer | 73,033 |
| Schlackman ScottDirector | 42,229 |
| Kiai ParsaDirector | 40,40621,089 held indirectly |
| Thomas Andrea BDirector | 35,697 |
| Geary Elizabeth A.Director | 31,225 |
| MacKenzie Jonathan BarrettVP, Finance & CAO | 20,838 |
| Rose Jeffrey MatthewDirector | 18,419 |
Questions about MED
What does Medifast Inc do?
Medifast Inc is a company in the Consumer staples sector, listed on NYSE as MED. Its shares trade on NYSE under the ticker MED.
What is Medifast Inc's net worth?
Medifast Inc has a market value (market cap) of $147.4M at the latest share price, and shareholders' equity of $180.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Medifast Inc profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $40.9M on revenue of $299.6M.
How much revenue does Medifast Inc make?
Over the twelve months to September 30, 2026 Medifast Inc reported revenue of $299.6M. That is 30.3% less than a year earlier.
When did Medifast Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 26, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 6, 2026.
When is Medifast Inc's next earnings report?
Medifast Inc's next report is expected around February 16, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare MED with
Follow MED
Get an email when Medifast Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Medifast Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.